Abstract
Background: MiR-582-5p has been demonstrated to protect against ischemic stroke. However, its implication in the progression of neonatal hypoxic-ischemic encephalopathy (HIE) has not been explored.
Methods: In this study, we used an in vitro model of oxygen-glucose deprivation (OGD) to investigate the protective effect of miR-582-5p on PC12 cells. OGD-induced inhibition of cell viability and promotion of cell death was assessed by CCK-8 assay and flow cytometry. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were utilized to examine the levels of inflammatory cytokines. The effects of miR-582-5p on OGD-induced oxidative injury were assessed by the determination of oxidative stress indicators. Furthermore, dual-luciferase reporter assay and gain-offunction assay were used to determine the mechanism of miR-582-5p in OGD-induced cell injury.
Results: The expression of miR-582-5p was reduced upon OGD treatment in PC12 cells. Overexpression of miR-582-5p inhibited OGD-induced PC12 cell injury by regulating cell viability, apoptosis, inflammatory responses, and oxidative stress. MiR-582-5p targeted and negatively regulated high mobility group box 1 (HMGB1). MiR-582-5p presented protective effects on OGD-induced PC12 cell injury by targeting HMGB1.
Conclusion: Our results indicated that miR-582-5p ameliorates neuronal injury by inhibiting apoptosis, inflammation, and oxidative stress through targeting HMGB1.
Keywords: HMGB1, inflammation, miR-582-5p, neonatal hypoxic-ischemic encephalopathy, oxygen glucose deprivation, oxidative stress.
[http://dx.doi.org/10.1007/s13760-020-01308-3] [PMID: 32112349]
[http://dx.doi.org/10.1038/aps.2013.89] [PMID: 23892271]
[http://dx.doi.org/10.3390/ijms17122078] [PMID: 27973415]
[http://dx.doi.org/10.1007/s11910-019-0916-0] [PMID: 30637551]
[http://dx.doi.org/10.1590/s0102-865020170040000002] [PMID: 28538801]
[http://dx.doi.org/10.1016/j.cca.2015.08.021] [PMID: 26320853]
[http://dx.doi.org/10.1016/j.jpeds.2017.10.060] [PMID: 29478510]
[http://dx.doi.org/10.2174/2211536605666160825151201] [PMID: 27568791]
[http://dx.doi.org/10.1016/j.neuropharm.2018.11.041] [PMID: 30716413]
[PMID: 30536321]
[http://dx.doi.org/10.1371/journal.pone.0217652] [PMID: 31170211]
[http://dx.doi.org/10.2147/OTT.S183940] [PMID: 30666128]
[http://dx.doi.org/10.2147/CMAR.S274835] [PMID: 33244270]
[http://dx.doi.org/10.1002/pros.22877] [PMID: 25176332]
[http://dx.doi.org/10.1016/j.omtn.2019.01.004] [PMID: 30852380]
[http://dx.doi.org/10.1016/j.bbagrm.2018.02.002] [PMID: 29421308]
[http://dx.doi.org/10.1016/j.neuroscience.2018.05.010] [PMID: 29777754]
[http://dx.doi.org/10.1096/fj.202002109RR] [PMID: 33559227]
[http://dx.doi.org/10.1021/acschemneuro.0c00084] [PMID: 32073822]
[http://dx.doi.org/10.1002/jcb.26477] [PMID: 29105819]
[http://dx.doi.org/10.1007/s12035-019-1491-8] [PMID: 30656514]
[http://dx.doi.org/10.3349/ymj.2020.61.8.660] [PMID: 32734729]
[http://dx.doi.org/10.1016/j.lfs.2020.117664] [PMID: 32304765]
[http://dx.doi.org/10.3390/ijms21134609] [PMID: 32610502]
[http://dx.doi.org/10.1016/j.ejphar.2020.173189] [PMID: 32417325]
[http://dx.doi.org/10.3389/fimmu.2018.01518] [PMID: 30013568]
[http://dx.doi.org/10.1016/j.intimp.2019.105779] [PMID: 31362164]
[http://dx.doi.org/10.3389/fncel.2019.00506] [PMID: 31920543]
[http://dx.doi.org/10.3389/fnins.2020.00847] [PMID: 32848589]
[PMID: 32096202]